Speciality: Oncology
Description:
Dr. Sushant Mittal kicked off the insightful session titled "CNS Clarity from Day One: Rethinking Early Diagnostic Strategies", joined by esteemed panelists Dr. Tarachand Gupta and Dr. Randeep Singh. The discussion opened with a strong emphasis on the clinical importance of early evaluation for central nervous system (CNS) involvement, especially in complex or aggressive disease presentations. Dr. Mittal highlighted how delays in CNS assessment can result in mismanagement or missed therapeutic windows, setting the tone for a thought-provoking exchange. Dr. Gupta and Dr. Singh added their expertise from neurology and oncology perspectives, offering valuable multidisciplinary insights.
The session explored how CNS evaluation at the time of initial diagnosis is gaining traction in clinical protocols. With advancements in neuroimaging, cerebrospinal fluid analysis, and molecular biomarkers, early detection of CNS disease has become more achievable and actionable. The panel discussed real-world challenges in integrating these strategies, including resource constraints and variability in presentation. Emphasis was placed on identifying high-risk patients early - particularly in oncology and infectious disease contexts - where CNS involvement can significantly affect prognosis and treatment pathways. The conversation also touched on the need for standardized screening protocols and decision-making frameworks that support clinicians across specialties.
Thank you to all who joined this informative session. Your engagement and curiosity continue to drive these meaningful conversations forward. Special thanks to Dr. Sushant Mittal, Dr. Tarachand Gupta, and Dr. Randeep Singh for sharing their expertise. Keep following us for more sessions focused on innovation, interdisciplinary practice, and cutting-edge strategies in healthcare. Together, we’re reshaping how diseases are diagnosed and managed - starting from day one.
See More Webinars @ Hidoc Webinars
1.
Laser Therapy Shows Promise for Brain Tumors
2.
NEJM: Pirtobrutinib is effective in CLL patients who have received prior BTK inhibitor therapy.
3.
Renewing the call for a national Cancer Patient's Bill of Rights
4.
Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.
5.
Cancer cells with thick glycocalyx barrier evade immune system better: study
1.
Comprehensive Applications in Oncology and Quality Improvement
2.
HPV Infection Review: Epidemiology, Risks, and Therapeutic Advances for Clinicians
3.
Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine
4.
Navigating the Unknown: A Guide to Living With Hurthle Cell Thyroid Cancer
5.
Checkpoint Inhibitors in Oncology: Advances in PD-1/PD-L1 and CTLA-4 Targeted Therapy
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
2.
From Guidelines to Practice: Hematology
3.
CNS Clarity from Day One: Rethinking Early Diagnostic Strategies in ALK+NSCLC
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation